Understanding the genetic changes that lead to kidney cancer.
Dissecting Convergent Somatic and Germline Alterations that Mediate the Origins and Evolution of Kidney Cancer
This study is looking at how certain genetic changes, both from family and those that happen over time, can influence the growth of clear cell kidney cancer, with the hope of finding better ways to treat patients based on their unique genetic makeup.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11004978 on NIH RePORTER |
What this research studies
This research investigates how both inherited and acquired genetic mutations contribute to the development of clear cell renal cell carcinoma (ccRCC), a common type of kidney cancer. By analyzing the interactions between these mutations, the study aims to uncover how they affect tumor growth and patient outcomes. The research employs advanced methodologies, including deep learning algorithms, to identify and catalog these genetic alterations, which could lead to more personalized treatment strategies for patients. The goal is to enhance our understanding of the genetic landscape of ccRCC and improve clinical decision-making.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with clear cell renal cell carcinoma or those with a family history of kidney cancer.
Not a fit: Patients with other types of kidney cancer or those without any genetic predisposition to kidney cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with kidney cancer.
How similar studies have performed: Previous research has shown promise in understanding genetic mutations in cancer, suggesting that this approach could yield valuable insights into kidney cancer as well.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Van Allen, Eliezer M — Dana-Farber Cancer Inst
- Study coordinator: Van Allen, Eliezer M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.